TheraRadar
← Back
Data updated: Jul 17, 2026

ADAPT

Specialty

ADAPT is a specialty pharmaceutical company focused on Ophthalmology, Infectious Disease, Cardiovascular.

1971
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

ADAPT's Key Drugs

ADAPT's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

ADAPT's Recent FDA Approvals

New NDA/BLA approvals for ADAPT over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

ADAPT's Therapeutic Areas

ADAPT's approved drugs and pipeline span 3 therapeutic areas, led by Ophthalmology and Infectious Disease. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Ophthalmology 50%
0 drugs Phase 3: 2
Infectious Disease 25%
0 drugs Phase 3: 1
Cardiovascular 25%
0 drugs Phase 3: 1

ADAPT's Top Competitors

ADAPT's closest competitors by therapeutic-area and drug-target overlap include Baxter, B BRAUN, and BAUSCH AND LOMB INC. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

ADAPT Pipeline Snapshot

ADAPT has 4 active clinical programs from ClinicalTrials.gov — 4 Phase 3, 0 Phase 2 and 0 Phase 1.

4
Phase 3
0
Phase 2
0
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Ophthalmology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling